Trials / Enrolling By Invitation
Enrolling By InvitationNCT06443463
Long-term Safety and Tolerability of BHV-7000
A Phase 2, Global, Multicenter, Long-term Safety Study Designed to Assess the Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy
- Status
- Enrolling By Invitation
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 660 (estimated)
- Sponsor
- Biohaven Therapeutics Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A study to determine if BHV- 7000 is safe and tolerable in adults with refractory focal onset epilepsy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BHV-7000 | BHV-7000 50 mg. Participants will take open-label investigational product (IP) once daily |
| DRUG | BHV-7000 | BHV-7000 75 mg. Participants will take open-label investigational product (IP) once daily |
Timeline
- Start date
- 2024-07-30
- Primary completion
- 2026-12-01
- Completion
- 2027-01-01
- First posted
- 2024-06-05
- Last updated
- 2026-04-17
Locations
284 sites across 27 countries: United States, Argentina, Australia, Austria, Belgium, Chile, Croatia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, India, Italy, Mexico, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, South Africa, Spain, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06443463. Inclusion in this directory is not an endorsement.